ReviewNature reviews. Urology2010
Management of prostate cancer in HIV-positive patients.
Review in Nature reviews. Urology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Rezvilutamide combined with ADT in an HIV-positive patient with high-volume mHSPC on efavirenz-based antiretroviral therapy: a case report.Frontiers in oncology · 2026Article
- A Contemporary Multidimensional Insight into the Clinical and Pathological Presentation of Urological Conditions Associated with HIV: A Narrative Review.Tropical medicine and infectious disease · 2025Review
- A clinical overview of people living with HIV and genitourinary cancer care.Nature reviews. Urology · 2024Review
- Management of Localized Prostate Cancer in Men With Human Immunodeficiency Virus: Analysis of a Large Retrospective Cohort.Clinical genitourinary cancer · 2023Article
- Safety and Tolerability of Carboplatin and Paclitaxel in Cancer Patients with HIV (AMC-078), an AIDS Malignancy Consortium (AMC) Study.The oncologist · 2022Article
- Inclusive Cancer Care: Rethinking Patients Living with HIV and Cancer.The oncologist · 2020Article
- Is There an Optimal Curative Option in HIV-Positive Men with Localized Prostate Cancer? A Systematic Review.Current urology · 2019Review
- HIV-1-infected cell-derived exosomes promote the growth and progression of cervical cancer.International journal of biological sciences · 2019Article
- Cancer care disparities in people with HIV in the United States.Current opinion in HIV and AIDS · 2017Review
- Cancer Treatment in Patients With HIV Infection and Non-AIDS-Defining Cancers: A Survey of US Oncologists.Journal of oncology practice · 2015Article
- Cancer treatment disparities in HIV-infected individuals in the United States.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2014Article
- Urological aspects of HIV and AIDS.Nature reviews. Urology · 2013Review
- Prostate Cancer Outcomes in Patients Living With HIV/AIDS Treated With Radiation Therapy: A Systematic Review.Advances in radiation oncologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Improved medical therapy for HIV-positive patients has helped delay the progression of HIV to AIDS and reduce AIDS deaths. This dramatically prolonged survival has resulted in increased detection of non-AIDS-defining malignancies, such as prostate cancer, in people with HIV. Reported prostate cancer incidences in HIV-positive men compared with the general population vary in different studies; however, its incidence in the general population has generally increased over time, owing to the widespread use of PSA testing and increased life expectancy. In the highly active antiretroviral therapy (HAART) era, evidence indicates that PSA kinetics and prostate cancer behavior are similar in HIV-positive and HIV-negative patients. Current American Urological Association (AUA) guidelines recommend screening of all men aged >or=40 years with a life expectancy >10 years, and HIV-positive patients should be included in this recommendation. Treatment options for HIV-positive patients with prostate cancer should include all those offered to the general population. Long-term treatment outcomes in HIV-positive patients remain uncertain; however, early results suggest response rates similar to those in HIV-negative patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.